Nelson Dusetti: A Strong Collaborative Study Addressing Resistance to RAS Inhibitors
Nelson Dusetti, Head of the Translational Research and Innovative Therapies Department at the Cancer Research Centre of Marseille (CRCM), shared on LinkedIn about recent paper by Vasiliki Liaki et al. published on biorRxiv:
“New preprint online!
We are proud to have contributed to a strong collaborative study led by our colleagues at CNIO – Spanish National Cancer Research Centre addressing resistance to RAS inhibitors in pancreatic cancer.
The study demonstrates that triple inhibition combining a RAS inhibitor (KRAShi), afatinib (EGFRi), and a STAT3 PROTAC (SD36) achieves complete and durable regression of pancreatic tumors in both murine and patient-derived models (PDOs and PDXs), with no relapse observed after more than 200 days and no signs of toxicity.
This work represents a major conceptual and therapeutic advance by showing that effective targeting of PDAC requires simultaneous inhibition of KRAS downstream (RAF1), upstream (EGFR), and parallel (STAT3) pathways.
The Marseille Pancreatic Cancer Team – CRCM – Marseille Cancer Research Center / Paoli-Calmettes Institute (IPC) is very happy to have contributed to this important international collaborative effort, reinforcing our commitment to translational oncology and to accelerating therapeutic innovation through high-resolution preclinical models.
Read the preprint.
Congratulations to Vasiliki Liaki, Mariano Barbacid, Carmen Guerra, and all co-authors for this remarkable work.”
Title: A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance
Authors: Vasiliki Liaki, Sara Barrambana, Myrto Kostopoulou, Carmen G. Lechuga, Ruth Álvarez, Rebeca Barrero, Silvia Jiménez-Parrado, Alejandra López-García, Lucia Morales-Cacho, Juan Carlos López-Gil, Elena Zamorano-Dominguez, Pian Sun, Blanca Rosas-Perez, Marta San Roman, Eduardo Caleiras, Matthias Drosten, Bruno Sainz Jr., Monica Musteanu, Nelson Dusetti, Valeria Poli, Francisco Sánchez-Bueno, Carmen Guerra, Mariano Barbacid
More posts featuring Nelson Dusetti.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023